AI-Enabled Drug Development: Best Practices for Mitigating Risks and Ensuring Good Governance

Join Winston’s Health Care & Life Sciences team for an insightful webinar featuring Intellectual Property partner Kathi Vidal, who recently returned to Winston after serving as Under Secretary of Commerce for Intellectual Property and Director of the USPTO since 2022.

Our attorneys will first discuss how generative AI is revolutionizing drug discovery, preclinical testing, and clinical trials. Then they will outline key associated risks in the areas of intellectual property, product liability, and data privacy while sharing actionable strategies to mitigate these risks and ensure robust AI governance.

Register here.

Connection details available once registered.

CLE INFORMATION

1.0 hour of CLE credit is offered for this webinar. Winston & Strawn LLP is an accredited CLE provider in California, Illinois, New York, Pennsylvania, and Texas. Florida and North Carolina CLE is pending. Other states available upon request.